If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 220.50
Bid: 220.50
Ask: 221.50
Change: -1.50 (-0.68%)
Spread: 1.00 (0.454%)
Open: 220.50
High: 221.00
Low: 220.00
Prev. Close: 222.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Puretech Health proposes $100m capital return

Tue, 19th Mar 2024 09:46

(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.

PureTech said on Tuesday that the proposed capital return represented approximately 14% of its market capitalisation based on Monday's closing price and noted that it follows a previous announcement that it will receive approximately $293.0m in gross proceeds from its remaining stake in Karuna.

The AIM-listed group said the offer will be launched after the publication of its full-year results in April, subject to market conditions, and will require shareholder approval.

PureTech added that if the full $100.0m was not returned, then it intends to return any remainder following the completion of the offer, by way of a special dividend.

Chief executive Daphne Zohar said: "PureTech's mission is to generate value both for patients and shareholders, and Bristol Myers Squibb's acquisition of our Founded Entity Karuna Therapeutics for $14.0bn is a testament to our execution on both fronts. We directed $18.5m to the founding and development of Karuna, and not only have we created a potential breakthrough treatment that may change the lives of millions of people living with schizophrenia, but we have also been able to generate $1.1bn in cash for PureTech, with potentially more to come. These resources enabled us to create an exciting crop of new medicines that position us to repeat and scale this type of outcome - and we have done so without diluting our shareholders in over six years.

"We are delighted to be able to purchase shares of PureTech at this valuation and to concurrently provide some liquidity to our shareholders and additional capital returns beyond the recently completed $50.0m share buyback. Following this proposed tender offer, we are confident that our strong balance sheet will continue to support the development of our existing pipeline - as well as the next wave of innovative medicines. Looking forward, the board will continue to assess ongoing opportunities to improve shareholder returns."

As of 1055 GMT, PureTech shares were up 8.58% at 221.50p.

Reporting by Iain Gilbert at Sharecast.com

More News
6 Oct 2021 06:06

IN BRIEF: PureTech Health's Vedanta posts positive VE303 trial results

IN BRIEF: PureTech Health's Vedanta posts positive VE303 trial results

Read more
5 Oct 2021 22:06

TRADING UPDATES: Inland gets Basildon permission; ICG assets grow

TRADING UPDATES: Inland gets Basildon permission; ICG assets grow

Read more
29 Sep 2021 18:23

TRADING UPDATES: Fulham Shore mulls dividend; LoopUp swings to loss

TRADING UPDATES: Fulham Shore mulls dividend; LoopUp swings to loss

Read more
10 Sep 2021 10:27

PureTech's Vor Biopharma granted FDA fast track for blood cancer drug

PureTech's Vor Biopharma granted FDA fast track for blood cancer drug

Read more
10 Sep 2021 07:38

PureTech Health's Vor wins FDA fast-track approval for cancer drug

(Sharecast News) - Clinical stage biotherapeutics firm PureTech Health on Friday said its founded entity, Vor Biopharma, had won US fast track approval for its leukaemia treatment.

Read more
24 Aug 2021 14:34

Tuesday broker round-up

(Sharecast News) - Coats: Jefferies starts at buy with 97.0p target price.

Read more
24 Aug 2021 13:13

PureTech Health hopes cash will carry it to 2025 amid first half loss

PureTech Health hopes cash will carry it to 2025 amid first half loss

Read more
24 Aug 2021 07:42

PureTech in 'strong' position despite swinging to net loss

(Sharecast News) - Biotechnology company PureTech Health swung to a loss in its first half, it said on Tuesday, amid rising costs.

Read more
23 Aug 2021 19:13

IN BRIEF: PureTech Health's LYT-100 performs well in Phase 1

IN BRIEF: PureTech Health's LYT-100 performs well in Phase 1

Read more
17 Aug 2021 16:07

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
17 Aug 2021 15:39

TRADING UPDATES: Chrysalis backs InfoSum; Argo Blockchain goes green

TRADING UPDATES: Chrysalis backs InfoSum; Argo Blockchain goes green

Read more
13 Aug 2021 14:45

EXECUTIVE CHANGES: Insig AI executive chair and Palace Capital CFO out

EXECUTIVE CHANGES: Insig AI executive chair and Palace Capital CFO out

Read more
11 Aug 2021 19:54

TRADING UPDATES: Ince launches solution; PureTech gets USD6.5 million

TRADING UPDATES: Ince launches solution; PureTech gets USD6.5 million

Read more
22 Jul 2021 15:35

Director dealings: Puretech Health director raises stake

(Sharecast News) - Puretech Health revealed on Thursday that director Bharatt Chowrira had acquired 25,000 ordinary shares in the FTSE 250-listed biotechnology company.

Read more
22 Jul 2021 14:54

DIRECTOR DEALINGS: Incoming Naked Wines chair buys USD175,000 worth

DIRECTOR DEALINGS: Incoming Naked Wines chair buys USD175,000 worth

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.